Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free JSPRW Stock Alerts

Jasper Therapeutics (JSPRW) Competitors

Jasper Therapeutics logo
$0.01 0.00 (0.00%)
As of 10:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

JSPRW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Jasper Therapeutics compare to Ainos?

Ainos (NASDAQ:AIMDW) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

In the previous week, Ainos had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.89 beat Ainos' score of 0.93 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ainos Positive
Jasper Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

Summary

Ainos beats Jasper Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to Alvotech?

Jasper Therapeutics (NASDAQ:JSPRW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. Jasper Therapeutics' average media sentiment score of 1.89 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
Jasper Therapeutics Very Positive
Alvotech Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Jasper Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Jasper Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

In the previous week, Jasper Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for Aravive. Jasper Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Jasper Therapeutics Very Positive

Summary

Aravive and Jasper Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does Jasper Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Jasper Therapeutics (NASDAQ:JSPRW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

In the previous week, Jasper Therapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Jasper Therapeutics' average media sentiment score of 1.89 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Very Positive
Atlantic Coastal Acquisition Corp. II Neutral

Summary

Jasper Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Jasper Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Jasper Therapeutics' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Very Positive
Jasper Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

Summary

Biofrontera and Jasper Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPRW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPRW vs. The Competition

Export
MetricJasper TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$429.91M$6.47B$11.77B
Dividend YieldN/A3.86%2.67%5.61%
P/E RatioN/A3.1824.5723.81
Price / SalesN/A6,477.34479.7984.86
Price / CashN/A13.1343.0554.72
Price / BookN/A83.8110.276.75
Net IncomeN/A-$96.07M$3.56B$337.26M
7 Day PerformanceN/A-0.56%-2.66%-1.98%
1 Month PerformanceN/A1.20%-0.06%0.86%
1 Year PerformanceN/A47.66%20.67%24.53%

Jasper Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPRW
Jasper Therapeutics
N/A$0.01
flat		N/A-87.9%$0.00N/AN/A20
AIMDW
Ainos
N/A$0.13
-0.3%		N/A+16.6%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.26
flat		N/A-91.9%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JSPRW) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel